Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius

Hematopoietic Stem Cell TransplantationA Global Perspective

(2010) Alois Gratwohl   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation

(2010) Paul J. Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire

(2010) M Mohty et al.   LEUKEMIA

Current Challenges in Chronic Graft-versus-Host Disease

(2009) Gerard Socie et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

(2009) Jürgen Finke et al.   LANCET ONCOLOGY

Chronic Graft-versus-Host Disease—Implementation of the National Institutes of Health Consensus Criteria for Clinical Trials

(2008) Linda M. Griffith et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION